Stay updated on Nivolumab Plus SBRT in Metastatic RCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus SBRT in Metastatic RCC Clinical Trial page.

Latest updates to the Nivolumab Plus SBRT in Metastatic RCC Clinical Trial page
- CheckyesterdayChange DetectedThe site footer revision changed from v3.8.0 to v3.8.1, with no visible change to the study record.SummaryDifference0.1%

- Check8 days agoChange DetectedThe NIVES clinical-trial record for nivolumab combined with stereotactic radiotherapy in metastatic renal cell carcinoma is displayed, including its completed status and study design. It also provides participant eligibility, treatment details, outcome measures, locations, and investigators.SummaryDifference43%

- Check15 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA notice about NIH’s terminology transition appears above the ClinicalTrials.gov page, and the site revision changes from v3.7.1 to v3.7.2. The study record remains unavailable behind a 403 error.SummaryDifference1%

- Check43 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now shows a 403 Forbidden error replacing the study record content, with a standard site header/footer and no trial details visible.SummaryDifference17%

Stay in the know with updates to Nivolumab Plus SBRT in Metastatic RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus SBRT in Metastatic RCC Clinical Trial page.